EPISODE · Jun 6, 2025 · 28 MIN
The Science of Myostatin inhibitors, GLP-1 meds and Muscle Mass
from Docs Who Lift · host Docs Who Lift
Dr. Grant Tinsley joins the discussion as the body composition expert.Myostatin is a key regulator of muscle growth.Wendy Whippete the most jacked muscled up dogThe concern of GLP-1 receptor agonists and muscle mass loss.Overview of Courage trial looking at semaglutide and trevogrumab and lean mass lossUpcoming Believe trial coming out (bimagrumab and semaglutide)Exercise remains crucial for muscle health and function.MRI data from SURPASS MRI provides new insights into muscle volume changes.The combination of medications may have varying effects on muscle mass.Caution is advised regarding the long-term effects of new drugs.Clinical benefits of medications often outweigh concerns about muscle loss.Future research will explore the synergy between exercise and medication.Other docs who lift podcasts with Dr. Grant:Tirzepatide muscle lossLean mass loss and GLP-1 meds Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Embed this episode
What this episode covers
In this episode of the Docs Who Lift podcast, Drs. Karl, Spencer, and Grant discuss the latest research on muscle growth, body composition, and the effects of GLP-1 receptor agonists. They delve into the role of myostatin in muscle regulation, the implications of recent trials on muscle mass loss, and the importance of exercise in maintaining muscle health. The conversation also touches on MRI data regarding muscle volume and the future of muscle-enhancing medications.
NOW PLAYING
The Science of Myostatin inhibitors, GLP-1 meds and Muscle Mass
No transcript for this episode yet
Similar Episodes
Similar Podcasts
No similar podcasts found.